FIELD: biotechnology.
SUBSTANCE: use of an isolated humanized protein binding to human glycoprotein VI (hereinafter – hGPVI) is proposed for the treatment of a condition associated with GPVI in a subject who needs it. The isolated humanized protein is injected to a subject during at least 2 hours, preferably during at least 4-6 hours. The specified protein is an antibody molecule or an antibody fragment.
EFFECT: invention provides for improved safety and tolerance, when the antibody is injected to a human, and it can be used for the prevention and/or treatment of human cardiovascular diseases.
12 cl, 9 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROTEIN BOUND WITH HUMAN GLYCOPROTEIN, COMPOSITION, PHARMACEUTICAL COMPOSITION, EXPRESSION VECTOR | 2016 |
|
RU2773819C2 |
| HUMAN ANTIBODIES BINDING TO ROR2 | 2018 |
|
RU2784586C2 |
| ANTIBODIES BINDING TO GPRC5D | 2019 |
|
RU2797268C2 |
| TRISPECIFIC BINDING PROTEINS BINDING CD38, CD28 AND CD3, AS WELL AS METHODS OF USE FOR TREATING VIRAL INFECTION | 2019 |
|
RU2820351C2 |
| ADAM9-BINDING MOLECULES AND THEIR APPLICATION METHODS | 2017 |
|
RU2783619C2 |
| IMPROVED TNF-BINDING AGENTS | 2016 |
|
RU2774823C2 |
| RGMa BINDING PROTEIN AND ITS USE | 2016 |
|
RU2809500C2 |
| ANTIBODIES WHICH BIND TO SORTILIN AND INHIBIT THE BINDING OF PROGRANULIN | 2016 |
|
RU2735639C2 |
| PD-L1 ANTIBODIES BINDING DOG PD-L1 | 2015 |
|
RU2722562C2 |
| ADAMTS-BINDING IMMUNOGLOBULINS | 2018 |
|
RU2781182C2 |
